Novo launches online news channel for hemophilia patients; Sanofi's MS pill slows brain atrophy in Phase III;

> Novo Nordisk ($NVO) has launched an online news channel as part of its new website for hemophilia patients, RareBleedingDisorders.com. More

> Sanofi's ($SNY) multiple sclerosis pill, Aubagio, slowed brain atrophy in a Phase III trial. Release

> The U.S. Department of Health and Human Services (HHS) is considering ideas to control drug prices, including contracting with drugmakers to pay based on performance. More (sub. req.)

> Formycon and Bioeq have launched a Phase III trial of their biosimilar of Roche's ($RHHBY) Lucentis. Report

And Finally... A guerrilla advertising campaign in Australia is encouraging gay men to have unprotected sex to promote Gilead's ($GILD) Truvada, which reduces the risk of contracting HIV. More

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.